US-based medical technology company Luminex has reported positive results from the evaluation of the ARIES System and Flu A/B and RSV CE-IVD Assay by the Department of Viroscience at Erasmus Medical Center in The Netherlands.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The Aries System is based on the universal assay protocol and extracts, amplifies and detects nucleic acid targets from multiple sample types and up to 12 different in vitro diagnostic (IVD) assays run together in random batches.

The higher throughput ARIES System provides two independent modules, each supporting one to six cassettes, allowing for both STAT and Batch testing of IVD and homebrew assays using MultiCode Reagents when using a universal assay protocol.

The ARIES Flu A/B and RSV Assay is used to detect and classify mainly three respiratory pathogens: influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) by examining nasopharyngeal swabs (NPS) specimens from patients exhibiting signs of respiratory tract infection.

"The study also underlines the importance of point of impact tests, where results have an immediate impact on patient care and clinical decision making, even outside normal office hours."

During the study, the ARIES platform and Flu A/B and RSV Assay demonstrated comparable high-clinical specificity and sensitivity and was proven superior to the established assays such as immunochromatographic tests and direct immunofluorescence assays.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The study also suggested the ease of usage of the systems compared to other rapid molecular test platforms.

Luminex EMEIA managing director Thomas Pracht said: "The Erasmus study demonstrates the quality and performance of the ARIES platform and the value of the system for molecular diagnostic labs that want to perform out of sync MDx testing in other words, outside of office hours testing or stat testing during office hours in between runs.

“The study also underlines the importance of point of impact tests, where results have an immediate impact on patient care and clinical decision making, even outside normal office hours."

Image: The ARIES Flu A/B and RSV Assay detects influenza virus. Photo: courtesy of Luminex Corporation.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact